Lumos Diagnostics (ASX:LDX) received the largest single purchase order for the company's point-of-care respiratory test, FebriDx, worth $126,000 from iMedical, according to a Wednesday filing with the Australian bourse.

The US Food and Drug Administration cleared FebriDx to be marketed in the US in July 2023 as an aid in diagnosing bacterial acute respiratory infection and distinguishing them from non-bacterial causes, the filing said.

Shares rose nearly 4% in afternoon trade Wednesday.